Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders

American Journal of Health-System Pharmacy

Volumn 68, Issue 4, 2011, Pages 347-352

  Traugott, Kristi A ^a   Maxwell, Pamela R ^b,c   Green, Kay ^d,e   Frei, Christopher ^f,g   Lewis II, James S ^e  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b Solid Organ Transplantation   (United States)

^c Department of Pharmacy Services ^*  (United States)

^d Neonatal Intensive Care Unit Baptist Health Lexington   (United States)

^e University Health System   (United States)

^f UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^g University of Texas Health Science Center   (United States)

Author keywords

Antibiotics; Blood levels; Computers; Dosage; Medication orders; Prescribing; Protocols; Rational therapy; Vancomycin

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; AMPHOTERICIN B; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFECTIVE AGENT; CONTRAST MEDIUM; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GANCICLOVIR; HYPERTENSIVE FACTOR; LITHIUM; NONSTEROID ANTIINFLAMMATORY AGENT; TACROLIMUS; VANCOMYCIN;

ADULT; ARTICLE; COMPUTERIZED PROVIDER ORDER ENTRY; CONTROLLED STUDY; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 79956033946     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090661     Document Type: Article

References (18)

1. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis. 1994; 18:533-43. (Pubitemid 24106903)
2. Moellering RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis. 1994; 18:544-6.
3. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006; 42(suppl 1):S35-9.
4. Darko W, Medicis JJ, Smith A et al. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy. 2003; 23:643-50. (Pubitemid 36539045)
5. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009; 66:82-98.
6. Paladino JA, Sunderlin JL, Adelman MH et al. Observations on vancomycin use in U.S. hospitals. Am J Health-Syst Pharm. 2007; 64:1633-41. (Pubitemid 47173543)
7. Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med. 2003; 163:1409-16. (Pubitemid 36758913)
8. McCluggage L, Lee K, Potter T et al. Implementation and evaluation of vancomycin nomogram guidelines in a computerized prescriber-order-entry system. Am J Health-Syst Pharm. 2010: 67:70-5.
9. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother. 1993; 27:594-8.
10. Pryka RD. Vancomycin serum concentration monitoring: a continued debate. Ann Pharmacother. 1994; 28:1397-9.
11. Leader WG, Chandler MH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet. 1995; 28:327-42.
12. James CW, Gurk-Turner C. Recommendations for monitoring serum vancomycin concentrations. Proc (Bayl Univ Med Cent). 2001; 14:189-90.
13. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 2001; 52(suppl 1):35S-43S.
14. Tobin CM, Darville JM, Thomson AH et al. Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. J Antimicrob Chemother. 2002; 50:713-8. (Pubitemid 35331689)
15. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet. 1994; 344:1748-50.
16. Bates DW, Soldin SJ, Rainey PM et al. Strategies for physician education in therapeutic drug monitoring. Clin Chem. 1998; 44:401-7. (Pubitemid 28087747)
17. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med. 2008; 36(suppl):S216-23.
18. Shapiro SS, Wilk MB. An analysis of variance test for normality. Biometrika. 1965; 52:591-611.